Keyphrases
All-cause Mortality
14%
Apremilast
44%
Budget Impact
14%
Clinical Prognosis
44%
Cluster Randomized Trial
44%
De-novo mutations
44%
Developmental Disorders
44%
Diabetes
44%
Diabetes Management
22%
Diagnosis Study
44%
Diagnosis Treatment
44%
Diagnostic Performance
47%
Disease Genome
44%
Economic Evaluation
44%
Epidermolysis Bullosa
44%
Equitable Access
44%
Exome
17%
Exome Sequencing
22%
Gene Panel
44%
General Practice
22%
Genetic Testing
25%
Genome Sequencing
59%
Genomic Medicine
23%
Genomic Testing
44%
Genomics England
22%
Hospitalization Rate
14%
Implications for Future
44%
Inherited Condition
44%
Ireland
44%
National Health Service
14%
NHS Scotland
18%
Parental Age
12%
Patients with Diabetes
44%
Position Statement
17%
Precision Diagnosis
44%
Precision Treatment
44%
Primary Care
22%
Prognosis Study
44%
Publicly Funded Healthcare Systems
53%
Rare Diseases
88%
Scotland
100%
Scottish
14%
Singleton
14%
T Helper 17 (Th17)
44%
Tayside
44%
Testing Services
16%
Timely Access
44%
Treatment Study
44%
Variant Prioritization
22%
Whole Genome Sequencing
44%
Medicine and Dentistry
All Cause Mortality
7%
Apremilast
44%
Blister
6%
Blister Fluid
12%
Cytokine
12%
Diabetes
44%
Diseases
16%
Eosinophil
6%
Epidermolysis Bullosa Simplex
44%
General Medicine
11%
Genetic Disorder
6%
Immunohistochemistry
6%
Incidental Finding
14%
Lymphocyte
6%
Medicine
14%
National Health Service
7%
Neutrophil
6%
Patient Experience
14%
Patient Support Group
14%
Patient with Diabetes
44%
Primary Health Care
11%
Prospective Study
6%
Rare Disease
44%
Real-Time Polymerase Chain Reaction
6%
Retrospective Study
6%
Skin Biopsy
6%
Skin Blistering
12%
T Helper 17 Cell
6%